2025-524218-27-00CompletedPhase 1
An open label, randomized, single-dose, two-treatment, two-period, cross-over bioequivalence study comparing Pyridostigmine Bromide, P.R.Tab, 180 mg/tab, VIANEX S.A., Greece versus Mestinon® retard 180 mg/prolonged-release tablet, Viatris Healthcare GmbH, Germany, in healthy male and female volunteers under fed conditions.
Source: EU CTIS (euclinicaltrials.eu) · Last updated 19 Dec 2025
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 44 (actual)
- First submitted
- 4 Dec 2025
- Start date
- 21 Jan 2026
- Lead sponsor
- Vianex S.A.
- EU CT number
- 2025-524218-27-00
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 44
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Cepha s.r.o. | Plzen 1 | Czechia | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.